Healome Therapeutics Secures £2M to Revolutionize Eye Care with Advanced Matrix Technology
July 11, 2026, 10:03 am
Location: United Kingdom, England, Northwich
Employees: 11-50
Founded date: 2012
Healome Therapeutics, a UK spinout, secured £2M seed funding. Its proprietary eye-drop matrix technology promises to transform ocular surface disease treatment. This innovation delivers sustained drug action, improving retention, lubrication, and healing. It targets widespread issues like dry eye and corneal damage, plus rare conditions such as Epidermolysis Bullosa. Empirical Ventures led the investment. Funds will advance preclinical development, scale manufacturing, and secure regulatory approvals (MHRA/FDA). Human trials are slated for 2027. This funding propels a significant leap in ophthalmic care.
A New Vision for Ophthalmology
Healome Therapeutics has secured substantial seed funding. A £2 million investment propels its innovative mission. The University of Birmingham spinout focuses on ocular surface diseases. It develops a proprietary eye-drop matrix technology. This innovation promises better eye care. Its launch marks a critical advance in ophthalmic solutions.
Pioneering an Advanced Platform
The core technology is an advanced eye-drop matrix. It functions uniquely. Administered as a liquid, it then restructures. A transparent, lubricating matrix forms on the eye's surface. This provides extended residence time. It ensures sustained drug delivery. This contrasts sharply with conventional eye drops. Standard drops offer limited contact time. They wash away quickly. This often necessitates frequent application. Such regimens challenge patient adherence. Healome's solution tackles this fundamental problem.
Addressing Critical Unmet Needs
Ocular surface diseases affect millions globally. Dry eye disease alone impacts over 350 million individuals. Its market value reaches $5 billion. The broader ocular surface disease market exceeds $12 billion. Current treatments often fall short. Patients suffer chronic discomfort. Vision can be severely compromised. Healome's technology offers a potent solution. It improves drug retention significantly. It enhances lubrication and protection. It accelerates healing processes. This addresses a major gap in patient care.
Versatile Delivery Capabilities
The platform exhibits remarkable versatility. It delivers various therapeutic payloads. Small molecules benefit greatly. Complex biologics also find a stable, effective delivery mechanism. Preclinical studies demonstrate its power. An anti-scarring biologic was successfully delivered. Severely injured and infected corneas showed rapid healing. Side effects remained minimal. This capability opens new, powerful treatment avenues. It broadens the scope of targeted therapies.
Targeting a Spectrum of Conditions
Healome targets multiple critical ophthalmic conditions. Dry eye disease is a primary focus area. Ocular surface inflammation also falls within its scope. Corneal injuries represent another key area of application. The platform promises improved chronic ophthalmic drug delivery. It also addresses rare diseases. Conditions causing severe ocular surface damage are particularly important. The technology's broad utility ensures wide impact.
Focus on Rare Diseases: Epidermolysis Bullosa
Part of the funding targets specific rare diseases. Epidermolysis Bullosa (EB) is one such critical focus. This rare genetic disorder affects approximately 500,000 people worldwide. Many EB patients face severe eye complications. These include chronic pain, recurrent corneal abrasions, and vision-threatening scarring. Investments from DEBRA Research and Cure EB directly support this critical development. Healome aims to alleviate immense suffering for these patients. It offers new hope where little existed.
The Power Behind the Funding
Empirical Ventures led this significant seed round. Other key participants include DEBRA Research, Cure EB, and Oshen Bio. Existing investor SFC Capital also contributed. This diverse investor base highlights strong confidence in Healome's potential. It underscores the urgent need for its technology. The investment signifies strong belief in its market impact.
Co-Founding Vision and Leadership
Healome’s foundation rests on strong scientific expertise. Professor Liam Grover, Professor Tony Metcalfe, Dr. Richard Moakes, and Dr. Richard Williams co-founded the company. Dr. Williams serves as CEO. This team brings deep knowledge of biomaterials and ophthalmology. Their collective vision drives this critical innovation. Experienced leadership guides the company's strategic path.
Strategic Path Forward
The capital secured has a clear purpose. A substantial portion advances preclinical development programs. Manufacturing scale-up is crucial. This ensures future production capacity. Engaging with regulatory bodies is paramount. Healome will work closely with the UK’s MHRA. It will also interact extensively with the U.S. FDA. These engagements pave the way for human trials. First-in-human clinical studies are projected for 2027. This timeline emphasizes swift progress.
Robust Intellectual Property
Healome has built a strong intellectual property portfolio. It holds five patent families. These cover its proprietary matrix architecture. The technology uses established pharmaceutical- and food-grade polymers. This design choice is strategic. It avoids complex chemical modifications. Such alterations often introduce manufacturing complexities. They can also prolong regulatory approval timelines. Healome's simpler approach offers a clear advantage. It streamlines development. It accelerates market entry.
Manufacturing and Regulatory Advantage
The reliance on established polymers offers a distinct benefit. These materials are already familiar to regulators. This eases the path for regulatory clearance. It reduces potential hurdles in both the UK and US markets. Manufacturing processes become more straightforward. This scalable approach supports future commercialization. Healome builds its technology on a solid, practical foundation. This ensures efficient, compliant development.
A Future of Enhanced Ocular Health
This funding marks a pivotal moment for Healome Therapeutics. The company is poised for significant impact. Its advanced eye-drop matrix technology offers new hope. It promises more effective, patient-friendly treatments. The company moves closer to human trials. It aims to transform countless lives. It sets a new standard for ocular care innovation. The future of eye health looks brighter. This investment propels a new era of ophthalmic therapy.
A New Vision for Ophthalmology
Healome Therapeutics has secured substantial seed funding. A £2 million investment propels its innovative mission. The University of Birmingham spinout focuses on ocular surface diseases. It develops a proprietary eye-drop matrix technology. This innovation promises better eye care. Its launch marks a critical advance in ophthalmic solutions.
Pioneering an Advanced Platform
The core technology is an advanced eye-drop matrix. It functions uniquely. Administered as a liquid, it then restructures. A transparent, lubricating matrix forms on the eye's surface. This provides extended residence time. It ensures sustained drug delivery. This contrasts sharply with conventional eye drops. Standard drops offer limited contact time. They wash away quickly. This often necessitates frequent application. Such regimens challenge patient adherence. Healome's solution tackles this fundamental problem.
Addressing Critical Unmet Needs
Ocular surface diseases affect millions globally. Dry eye disease alone impacts over 350 million individuals. Its market value reaches $5 billion. The broader ocular surface disease market exceeds $12 billion. Current treatments often fall short. Patients suffer chronic discomfort. Vision can be severely compromised. Healome's technology offers a potent solution. It improves drug retention significantly. It enhances lubrication and protection. It accelerates healing processes. This addresses a major gap in patient care.
Versatile Delivery Capabilities
The platform exhibits remarkable versatility. It delivers various therapeutic payloads. Small molecules benefit greatly. Complex biologics also find a stable, effective delivery mechanism. Preclinical studies demonstrate its power. An anti-scarring biologic was successfully delivered. Severely injured and infected corneas showed rapid healing. Side effects remained minimal. This capability opens new, powerful treatment avenues. It broadens the scope of targeted therapies.
Targeting a Spectrum of Conditions
Healome targets multiple critical ophthalmic conditions. Dry eye disease is a primary focus area. Ocular surface inflammation also falls within its scope. Corneal injuries represent another key area of application. The platform promises improved chronic ophthalmic drug delivery. It also addresses rare diseases. Conditions causing severe ocular surface damage are particularly important. The technology's broad utility ensures wide impact.
Focus on Rare Diseases: Epidermolysis Bullosa
Part of the funding targets specific rare diseases. Epidermolysis Bullosa (EB) is one such critical focus. This rare genetic disorder affects approximately 500,000 people worldwide. Many EB patients face severe eye complications. These include chronic pain, recurrent corneal abrasions, and vision-threatening scarring. Investments from DEBRA Research and Cure EB directly support this critical development. Healome aims to alleviate immense suffering for these patients. It offers new hope where little existed.
The Power Behind the Funding
Empirical Ventures led this significant seed round. Other key participants include DEBRA Research, Cure EB, and Oshen Bio. Existing investor SFC Capital also contributed. This diverse investor base highlights strong confidence in Healome's potential. It underscores the urgent need for its technology. The investment signifies strong belief in its market impact.
Co-Founding Vision and Leadership
Healome’s foundation rests on strong scientific expertise. Professor Liam Grover, Professor Tony Metcalfe, Dr. Richard Moakes, and Dr. Richard Williams co-founded the company. Dr. Williams serves as CEO. This team brings deep knowledge of biomaterials and ophthalmology. Their collective vision drives this critical innovation. Experienced leadership guides the company's strategic path.
Strategic Path Forward
The capital secured has a clear purpose. A substantial portion advances preclinical development programs. Manufacturing scale-up is crucial. This ensures future production capacity. Engaging with regulatory bodies is paramount. Healome will work closely with the UK’s MHRA. It will also interact extensively with the U.S. FDA. These engagements pave the way for human trials. First-in-human clinical studies are projected for 2027. This timeline emphasizes swift progress.
Robust Intellectual Property
Healome has built a strong intellectual property portfolio. It holds five patent families. These cover its proprietary matrix architecture. The technology uses established pharmaceutical- and food-grade polymers. This design choice is strategic. It avoids complex chemical modifications. Such alterations often introduce manufacturing complexities. They can also prolong regulatory approval timelines. Healome's simpler approach offers a clear advantage. It streamlines development. It accelerates market entry.
Manufacturing and Regulatory Advantage
The reliance on established polymers offers a distinct benefit. These materials are already familiar to regulators. This eases the path for regulatory clearance. It reduces potential hurdles in both the UK and US markets. Manufacturing processes become more straightforward. This scalable approach supports future commercialization. Healome builds its technology on a solid, practical foundation. This ensures efficient, compliant development.
A Future of Enhanced Ocular Health
This funding marks a pivotal moment for Healome Therapeutics. The company is poised for significant impact. Its advanced eye-drop matrix technology offers new hope. It promises more effective, patient-friendly treatments. The company moves closer to human trials. It aims to transform countless lives. It sets a new standard for ocular care innovation. The future of eye health looks brighter. This investment propels a new era of ophthalmic therapy.